R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
- Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board
- Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease
- Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of Medicine
Redwood City, California – 30 June 2026 – R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced the formation of its Scientific Advisory Board (SAB), comprising seven internationally renowned experts in the field of nephrology, chaired by Glenn Chertow, M.D. (Stanford University School of Medicine).
